share_log

BioNexus Gene Lab Announces A $250K Strategic Investment By Its Wholly Owned Subsidiary, MRNA Scientific, In Ascension Innovation Sdn Bhd Underscoring BGLC's Commitment To Advancing Healthcare Solutions Through Cutting-Edge AI And Predictive Analytics.

BioNexus Gene Lab Announces A $250K Strategic Investment By Its Wholly Owned Subsidiary, MRNA Scientific, In Ascension Innovation Sdn Bhd Underscoring BGLC's Commitment To Advancing Healthcare Solutions Through Cutting-Edge AI And Predictive Analytics.

Bionexus基因實驗室宣佈其全資子公司MRNA Scientific向Ascension Innovation Sdn Bhd進行25萬美元的戰略投資，這突顯了BGLC致力於通過尖端的人工智能和預測分析推進醫療保健解決方案的承諾。
Benzinga ·  04/19 01:52

BioNexus Gene Lab Corporation (NASDAQ:BGLC), a global leader in genomic diagnostics and healthcare technology, announces a strategic investment by its wholly owned subsidiary, MRNA Scientific Sdn Bhd, in Ascension Innovation Sdn Bhd (AISB), a privately held Malaysian company. This investment underscores BGLC's commitment to advancing healthcare solutions through cutting-edge AI and predictive analytics.

基因組診斷和醫療保健技術的全球領導者Bionexus基因實驗室公司（納斯達克股票代碼：BGLC）宣佈其全資子公司MRNA Scientific Sdn Bhd對馬來西亞私營公司Ascension Innovation Sdn Bhd（AISB）進行戰略投資。這項投資凸顯了BGLC致力於通過尖端的人工智能和預測分析來推進醫療保健解決方案的承諾。

Background:

背景：

● MRNA Scientific Sdn Bhd:
● MRNA Scientific Sdn Bhd：
○

A wholly-owned subsidiary of BGLC, MRNA Scientific specializes in blood-based genomic screening and dynamic genome profiling.

MRNA's innovative techniques enable early disease detection, personalized health management, and AI-driven insights.
○

作爲BGLC的全資子公司，MRNA Scientific專門從事基於血液的基因組篩查和動態基因組分析。

MRNA 的創新技術可以實現早期疾病檢測、個性化健康管理和人工智能驅動的見解。
● Ascension Innovation Sdn Bhd (AISB):
● Ascension Innovation Sdn Bhd (AISB)：
○ AISB is a trailblazer in healthcare technology, committed to enhancing patient experiences and outcomes.
○ Their flagship platform, aiCMS, empowers clinics, physicians, and patients to have better control over healthcare delivery through personalized patient health management.
○ AISB是醫療保健技術的開拓者，致力於改善患者體驗和療效。
○ 他們的旗艦平台AICMS使診所、醫生和患者能夠通過個性化的患者健康管理更好地控制醫療服務的提供。

Strategic Investment and Handover Ceremony:

戰略投資和移交儀式：

· MRNA Scientific's investment of RM 1.2 million (approx. USD $250k) will occur in two tranches. The Company has made an initial payment of approx. RM 100k, to be followed by a final payment of RM 1.1million, subject to a formal agreement. Our investment in AISB signifies a strategic move to accelerate healthcare innovation. The investment, funded internally, is expected to constitute an indicative equity of approximately 10% of the ordinary shares in AISB upon completion.
· The infusion of capital will further AISB's development and accelerate its AI rollout, including:
· MRNA Scientific的120萬令吉（約合25萬美元）的投資將分兩批進行。根據正式協議，該公司已支付約10萬令吉的首期付款，隨後是110萬令吉的最後一筆款項。我們對AISB的投資標誌着加速醫療創新的戰略舉措。這項由內部融資的投資預計將在完成後構成約10％的AISB普通股的指示性股權。
· 注入資金將進一步推動AISB的發展並加速其人工智能的推出，包括：
o AI Assistance in the Clinic and on-App: The AI features include the integration of predictive and generative AI note taking/analysis and diagnosis aids via Large Language Model (LLM), voice transcription, and natural language assistance for service selection and bookings.
o Predictive Analytics and Personalized Solutions: aiCMS will enhance early disease detection and personalized health recommendations in clinic and on-app, with the integration of in-app predictive health and wellness recommendations, medical translation services, and AI medical image analysis.
o 診所和應用程序內的人工智能協助：人工智能功能包括通過大型語言模型 (LLM) 整合預測性和生成式 AI 筆記/分析和診斷輔助工具、語音轉錄以及用於服務選擇和預訂的自然語言幫助。
o 預測分析和個性化解決方案：AICMS將整合應用內預測性健康和保健建議、醫學翻譯服務以及人工智能醫學圖像分析，從而增強臨床和應用程序中的早期疾病檢測和個性化健康建議。

Ceremony Participants:

儀式參與者：

· MRNA Scientific Directors:
· MRNA 科學總監：
o Mr. Kenny Lai
o Mr. CC Wong
o 黎健威先生
o CC Wong 先生
· AISB Directors:
· AISB 董事：
o Mr. Andrew Teng (Chief Executive Officer, CEO)
o Mrs. Penny Attenbrough (Chief Strategy Officer, CSO)
o 安德魯·滕先生（首席執行官、首席執行官）
o Penny Attenbrough 夫人（首席戰略官，CSO）

Expanding Market Reach:

擴大市場覆蓋面：

· MRNA Scientific and BGLC believe that this strategic investment will allow BGLC's Blood-based Genomic Screening (BGS) liquid biopsies and other diagnostic services to be better marketed and accessible to a wider range of customers and healthcare providers, through integration into AISB's aiCMS and the aiCARE app, enabling direct booking via healthcare providers and patients.
· By combining MRNA's expertise in genomics and AISB's innovative platform, patients and healthcare professionals will benefit from advanced diagnostics and personalized care.
· MRNA Scientific和BGLC認爲，這項戰略投資將通過整合到AISB的AICM和AiCare應用程序，使BGLC的血液基因組篩查（BGS）液體活檢和其他診斷服務能夠更好地推向市場，讓更多的客戶和醫療保健提供者獲得這些服務，從而實現通過醫療保健提供者和患者直接預訂。
· 通過將MRNA在基因組學方面的專業知識與AISB的創新平台相結合，患者和醫療保健專業人員將受益於先進的診斷和個性化護理。

Digital Health & AI Market:

數字健康與人工智能市場：

· The global digital health market size was estimated at USD 240.9 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 21.9% from 2024 to 20301.
· The global market size for AI in Healthcare is expected to reach USD 187.7 billion by 2030 with a compound annual growth rate (CAGR) of 38.5% from 2024 to 20302.
· Given the market size and opportunities in Digital Health and AI in Healthcare, MRNA and BGLC will closely consider opportunities to increase our participation in this market, including the potential to increase our investment in AISB and other technology platforms.
· 據估計，2023年全球數字醫療市場規模爲2409億美元，預計從2024年到20301年將以21.9％的複合年增長率（CAGR）增長。
· 到2030年，醫療領域人工智能的全球市場規模預計將達到1877億美元，從2024年到20302年，複合年增長率（CAGR）爲38.5％。
· 鑑於數字健康和醫療保健人工智能的市場規模和機遇，MRNA和BGLC將仔細考慮增加我們在該市場的參與的機會，包括增加對AISB和其他技術平台投資的可能性。

AISB's Projections:

AISB的預測：

· Projected Revenue in Malaysia:
· 馬來西亞的預計收入：
o As stated in its investment documents, AISB anticipates substantial revenue growth driven by increased adoption of aiCMS, with projections reaching RM 75million collectively for 2024-2028.
o The platform's comprehensive suite of services positions it as a game-changer in the Malaysian healthcare landscape.
o These revenue projections were part of the approved prospectus on the Securities Commission of Malaysia approved pitchIN Funding platform.
o 正如其投資文件中所述，AISB預計，由於AICM的採用率的提高，收入將大幅增長，預計2024-2028年總收入將達到7500萬令吉。
o 該平台的全方位服務使其成爲馬來西亞醫療保健領域的遊戲規則改變者。
o 這些收入預測是馬來西亞證券委員會批准的Pitchin Funding平台批准的招股說明書的一部分。
· Clinics and Service Providers:
· 診所和服務提供商：
o AISB aims to onboard a significant number of healthcare and wellness providers, and corporations.
o Since its recent launch, aiCMS has already proven market traction with over 30 healthcare providers and corporations in its initial segue into this broad market.
o AISB的目標是招募大量的醫療保健和保健提供商和公司。
o 自最近推出以來，AICMS已經證明了市場吸引力，最初有30多家醫療保健提供商和公司進入這個廣闊的市場。
· User Base and Health Records:
· 用戶群和健康記錄：
o With 145,000+ registered users and 340,000+ individual health records in its database, the aiCMS platform is already making an impact in the market.
o The platform's scalability has the potential for exponential growth.
o AICMS平台擁有超過14.5萬名註冊用戶，其數據庫中有340,000多條個人健康記錄，已經在市場上產生了影響。
o 該平台的可擴展性有可能實現指數級增長。

Quotes:

語錄：

· Mr. Sam Tan, CEO, BioNexus Gene Lab Corporation: "Our investment in AISB reflects our belief in their transformative healthcare solutions. Together, we aim to revolutionize patient care through predictive and generative AI."
· Mr. Andrew Teng, CEO, Ascension Innovation Sdn Bhd: "We welcome MRNA Scientific's support and look forward to leveraging their expertise. The future of healthcare lies in predictive analytics and personalized solutions."
· 陳山先生，BioneXUS 基因實驗室公司首席執行官：“我們對AISB的投資反映了我們對他們的變革性醫療解決方案的信念。我們的共同目標是通過預測性和生成式人工智能徹底改變患者護理。”
· 騰昇創新私人有限公司首席執行官安德魯·滕先生: “我們歡迎MRNA Scientific的支持，並期待利用他們的專業知識。醫療保健的未來在於預測分析和個性化解決方案。”

The handover ceremony took place at the Apollo Men's Wellness Centre in Starhill, Kuala Lumpur on April 18th, 2024, witnessed by Mr. Sam Tan, Chief Executive Officer of BioNexus Gene Lab Corp (BGLC).

移交儀式於2024年4月18日在吉隆坡Starhill的阿波羅男士健康中心舉行，Bionexus基因實驗室公司（BGLC）首席執行官山姆·陳先生見證。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論